The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation

Avapritinib is a protein kinase inhibitor designed to selectively inhibit oncogenic KIT and platelet-derived growth factor receptor alpha (PDGFRA) mutants by targeting the active conformation of the kinase. On 24 September 2020, a marketing authorisation valid through the European Union was issued f...

Descripción completa

Detalles Bibliográficos
Autores principales: Trullas-Jimeno, A., Delgado, J., Garcia-Ochoa, B., Wang, I., Sancho-Lopez, A., Payares-Herrera, C., Dalhus, M.L., Strøm, B.O., Egeland, E.J., Enzmann, H., Pignatti, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165402/
https://www.ncbi.nlm.nih.gov/pubmed/34023541
http://dx.doi.org/10.1016/j.esmoop.2021.100159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165402/
https://www.ncbi.nlm.nih.gov/pubmed/34023541
http://dx.doi.org/10.1016/j.esmoop.2021.100159

Ejemplares similares